In addition, the combination treatment of AZD-1950 (an antisense-STAT3 based drug) and durvalumab currently enters the phase II of the clinical trials for pancreatic cancer patients (NCT02983578). This evidence concerns the gene STAT3 and pancreatic neoplasm.